Technical Analysis for KPTI - Karyopharm Therapeutics Inc.

Grade Last Price % Change Price Change
F 8.395 3.13% 0.26
KPTI closed up 0.37 percent on Thursday, May 6, 2021, on 1.48 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical KPTI trend table...

Date Alert Name Type % Chg
Lizard Bullish Bullish Day Trade Setup 3.13%
Doji - Bullish? Reversal 3.13%
Lower Bollinger Band Walk Weakness 3.13%
New 52 Week Low Weakness 3.13%
Below Lower BB Weakness 3.13%
Oversold Stochastic Weakness 3.13%
MACD Bearish Signal Line Cross Bearish 3.51%
New 52 Week Closing Low Bearish 3.51%
New 52 Week Low Weakness 3.51%
Below Lower BB Weakness 3.51%
Older End-of-Day Signals for KPTI ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 4 hours ago
Up 1 ATR about 4 hours ago
Up 5% about 6 hours ago
Lizard Bullish Entry about 6 hours ago
Rose Above Previous Day's High about 6 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Karyopharm Therapeutics Inc. Description

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company's lead drug candidate includes Selinexor, an oral selective inhibitors of nuclear export (SINE) compound that specifically blocks XPO1 cargo binding is in Phase I clinical trials in patients with heavily pretreated relapsed and/or refractory hematological and solid tumor malignancies. Its other drug candidates comprise KPT-350 and related SINE compounds; PAK4 inhibitors; and Verdinexor, a SINE compound that is in Phase IIb clinical trials in pet dogs with newly-diagnosed or first relapse after chemotherapy lymphomas. The company was founded in 2008 and is based in Natick, Massachusetts.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Cancer Pharmaceutical Diseases Treatment Of Cancer Oncology Lymphoma Chemotherapy Occupational Safety And Health Stage Pharmaceutical Dogs Antibody Drug Conjugates Pixantrone

Is KPTI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 21.82
52 Week Low 7.79
Average Volume 1,989,097
200-Day Moving Average 14.31
50-Day Moving Average 10.76
20-Day Moving Average 9.46
10-Day Moving Average 9.15
Average True Range 0.55
ADX 29.56
+DI 12.53
-DI 36.60
Chandelier Exit (Long, 3 ATRs ) 9.07
Chandelier Exit (Short, 3 ATRs ) 9.43
Upper Bollinger Band 10.59
Lower Bollinger Band 8.32
Percent B (%b) -0.08
BandWidth 24.06
MACD Line -0.65
MACD Signal Line -0.59
MACD Histogram -0.0613
Fundamentals Value
Market Cap 599.11 Million
Num Shares 73.6 Million
EPS -3.55
Price-to-Earnings (P/E) Ratio -2.29
Price-to-Sales 12.93
Price-to-Book 14.87
PEG Ratio -0.15
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.80
Resistance 3 (R3) 8.76 8.49 8.69
Resistance 2 (R2) 8.49 8.33 8.52 8.65
Resistance 1 (R1) 8.32 8.22 8.36 8.36 8.62
Pivot Point 8.05 8.05 8.08 8.08 8.05
Support 1 (S1) 7.88 7.89 7.92 7.92 7.66
Support 2 (S2) 7.61 7.78 7.64 7.63
Support 3 (S3) 7.44 7.61 7.59
Support 4 (S4) 7.48